Harris · Nature communications 2021 · Pooled prospective cohort study · n=42466

Blood n-3 fatty acid levels and total and cause-specific mortality from 17 prospective studies.

Cited 242 times in the scientific literature.

Level 3 - non-randomized controlled study

De novo pooled analysis of 17 prospective observational cohort studies.

PubMed 33888689 · doi:10.1038/s41467-021-22370-2 · record verified 2026-08-30

What was done

A de novo pooled analysis of 17 prospective cohort studies evaluated the associations between circulating blood omega-3 fatty acid levels and mortality among 42,466 individuals tracked over a median of 16 years (15,720 total deaths). Analyses adjusted for multivariable risk factors and evaluated individual fatty acids including eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), docosahexaenoic acid (DHA), and alpha-linolenic acid (ALA).

What was found

Individuals in the highest quintile of circulating long-chain marine omega-3 fatty acids (EPA, DPA, DHA) had a 15% to 18% lower risk of death from all causes compared to the lowest quintile (at least p < 0.003 after multivariable adjustment). Similar reductions were observed for deaths from cardiovascular disease, cancer, and other causes. No significant association with mortality was observed for the plant-derived 18-carbon omega-3, alpha-linolenic acid.

Why it matters

This large-scale pooled analysis indicates that circulating biomarker levels of marine-derived long-chain omega-3s, but not plant-derived ALA, are consistently linked to reduced premature death across diverse cohort populations.

Limits

The observational design cannot establish causality or rule out residual lifestyle confounding. Blood biomarker levels were likely measured at a single baseline time point, which may not capture long-term variation. The abstract does not report specific hazard ratios, confidence intervals, or subgroup characteristics.

Cited by